Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease

American Heart Journal

Volumn 142, Issue 4, 2001, Pages 733-739

  Gianetti, Jacopo ^a   De Caterina, Maurizio ^b   De Cristofaro, Tiziana ^b   Ungaro, Biagio ^e   Del Guercio, Raffaello ^c   De Caterina, Raffaele ^a,d  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; PROSTAGLANDIN E1; PROSTAVASIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MALE; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REMISSION; BLOOD; CLINICAL TRIAL; EXERCISE TEST; FIBRINOLYSIS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PAIN ASSESSMENT; PERIPHERAL VASCULAR DISEASE; STATISTICS; TREATMENT OUTCOME;

AGED; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; EXERCISE TEST; FEMALE; FIBRINOLYSIS; HUMANS; INFUSIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PAIN MEASUREMENT; PERIPHERAL VASCULAR DISEASES; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034741124     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.118109     Document Type: Article

References (46)

1. Lower-limb arterial disease
2. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication
3. Effects of adjuvant PGE1 therapy following profound angioplasty in patients with severe limb ischemia: Early and long-term results
4. Recanalization of chronic peripheral arterial occlusions by alternating intra-arterial rt-PA and PGE1
5. Renal vasodilatory activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins
6. Synergism between PGE1-metabolites and nitric oxide on platelet aggregation
7. Analysis of effects of adrenaline and collagen on the activity of prostaglandin E1-stimulated human platelet adenylyl cyclase
8. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical limb ischemia: A placebo-controlled multicenter trial
9. L-arginine induces NO-dependent vasodilation in patients with critical limb ischemia: A randomized, controlled study
10. Prostanoid drug therapy for peripheral arterial occlusive disease - The European experience
11. Pathophysiology of the critical limb ischemia
12. Biochemical activation: An emerging paradigm in endothelial adhesion biology
13. Focal expression of intercellular adhesion molecule-1 in the human carotid bifurcation
14. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: Implications for the mode of progression of advanced coronary atherosclerosis
15. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin and thrombomodulin
16. Circulating ICAM-1 and VCAM-1 in peripheral arterial disease and hypercholesterolaemia: Relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events
17. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate af atherosclerosis
18. Circulating adhesion molecules are correlated with ultrasound assessment of carotid atherosclerosis
19. Smoking, hemostatic function and lipid peroxides in a population case-control study of peripheral arterial disease
20. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease
21. Association of variables of coagulation, fibrinolysis and acute phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
22. Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease
23. Relation of haemostatic, fybrinolytic and rheological variables to the angiographic extent of PAOD
24. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging
25. Impairment of the postural veno-arteriolar response in young type-1 diabetic patients: A study by laser-Doppler flowmetry
26. Development of an illness-specific instrument for assessment of quality of life in patients with arterial occlusive disease
27. Relevance of claudication pain distance in patients with peripheral arterial occlusive disease
28. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature
29. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Concensus (TASC), B: Intermittent claudication
30. Mechanisms of inflammation and leukocyte activation
31. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated cultured endothelial cells
32. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor
33. Inhibitory effect of prostaglandin E1 on intimal thickening following photochemically induced endothelial injury in the rat femoral artery
34. PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique
35. Short-term treatment with PGE1 analogue has long-term effects on intimal thickening in balloon-injured rat carotid arteries
36. 1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivo
37. Do E-series prostaglandins and their metabolites influence oxidation of native and glycated low-density lipoproteins?
38. The role of the endothelium in vascular homeostasis
39. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
40. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
41. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris
42. Relation between endothelial-cell activation and infection, inflammation and infarction
43. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
44. Blood coagulation and fibrinolysis activation during sudden arterial occlusion of lower extremities: An association with ischemia and patient outcome
45. Omega-3 fatty acids and endothelial leukocyte adhesion molecules
46. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines